Given that TROP2‐high CRC exhibited elevated HIF‐1α‐dependent lactate production activity to support metastatic progression, combining acriflavine with chemotherapy, or other targeted therapies may provide a promising strategy to prevent disease progression, thereby prolonging survival of CRC patients with metastasis. The gene discussed is TACSTD2; the disease is colorectal carcinoma.